Sanofi expanded its vaccine portfolio through a deal that added Dynavax’s hepatitis B vaccine and a shingles candidate, according to a deals report. The transaction transfers vaccine assets and pipeline candidates to Sanofi as part of the company’s strategy to bolster infectious‑disease offerings and accelerate late‑stage programs. The move follows broader consolidation in the vaccine sector and gives Sanofi immediate clinical assets to integrate into its global development and commercialization infrastructure. Analysts will track regulatory timelines and how the assets fit within Sanofi’s existing vaccine franchise.